Vanderbilt University

The article profiles various professionals in health and statistics, including John R. Lumpkin, M.D., M.P.H., Mollyann Brodie, Ph.D., Kennon R. Copeland, Ph.D., Tara Das, Ph.D., M.P.H., M.L.I.S., Scott H. Holan, Ph.D., V. Joseph Hotz, Ph.D., Bradley Malin, Ph.D., Sally C. Morton, Ph.D., Lucila Ohno-Machado, M.D., M.B.A., Ph.D., Andy Peytchev, Ph.D., C. Matthew Snipp, Ph.D., Kelly Hoover Thompson, J.D., and David R. Williams, Ph.D., detailing their roles, achievements, and contributions to their respective fields.

ZeroEyes' AI gun detection system implemented at Lane Dermatology, Sweden sees decline in melanoma among under-50s, study finds higher phthalate levels in young children using personal care products, Mary-Margaret Chren to retire from Vanderbilt and join Stanford, Medscape Education partners with Comprehensive Medical Mentoring Program to enhance dermatology diversity, NY Governor Kathy Hochul diagnosed with basal cell carcinoma.

Cancer patients with Duffy-null phenotype, common in African Americans, face exclusion from clinical trials due to naturally low neutrophil counts, highlighting racial bias in medical norms. A study in JAMA Network Open reveals 76.5% of trials and 53.5% of drug regimens unfairly exclude Duffy-null individuals, impacting treatment and survival.

Planes harbor germs on tray tables, bathroom handles, and drink cans, with studies showing high bacteria levels. Despite COVID-era cleaning improvements, concerns persist about cleanliness and airborne disease transmission. Experts recommend good hygiene and possibly masking to reduce infection risks.

A University of Minnesota study found hydroxychloroquine, taken once or twice weekly, did not significantly prevent COVID-19 in healthcare workers compared to placebo. The trial involved 1,483 participants, with side effects more common in hydroxychloroquine groups. No increased risk of serious side effects was noted.

Tecovirimat, an antiviral drug by Siga Technologies, showed no reduction in lesion resolution time or pain effect in adults with mild to moderate clade II mpox, per an interim analysis. No safety issues were found. The study's Data Safety and Monitoring Board recommended halting further enrollment, accepted by NIAID, which also closed an open-label study arm due to lack of efficacy. The findings highlight the importance of randomized clinical trials during outbreaks.